Margaret Koziel News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Gonorrhea Is Becoming Drug Resistant Scientists Just Found a Solution

A new antibiotic, zoliflodacin, is as effective as the current standard of care. Its creation may hasten the arrival of other needed antibiotics.

United statesJeanne marrazzoMargaret kozielManica balasegaramRamanan laxminarayanGlobal antibiotic research development partnershipEuropean unionNational institute of allergyPrinceton universityWhy it mattersGlobal antibiotic researchDevelopment partnershipBack storyInnoviva specialtyNational instituteDont know

Gonorrhea treatment: New antibiotic shows promise for drug-resistant infection

Gonorrhea treatment: New antibiotic shows promise for drug-resistant infection
nbcnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nbcnews.com Daily Mail and Mail on Sunday newspapers.

France generalUnited statesSouth africaMargaret kozielJeffrey klausnerManica balasegaramJeanne marrazzoJean michel molinaGlobal antibiotic research development partnershipKeck school of medicineUniversity of parisNational institute of allergyCenters for diseaseDrug administrationMassachusetts department of public healthWorld health organization

New antibiotic shows promise for drug-resistant gonorrhea

New antibiotic shows promise for drug-resistant gonorrhea
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

France generalSouth africaUnited statesJean michel molinaManica balasegaramJeffrey klausnerMargaret kozielJeanne marrazzoCenters for diseaseGlobal antibiotic research development partnershipKeck school of medicineDrug administrationMassachusetts department of public healthWorld health organizationUniversity of parisNational institute of allergy

Innoviva - XACDURO, the First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia in Adults

WALTHAM - Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. , today announced that XACDURO is now available in the United States for patients 18 years of age and older for the.

United statesPavel raifeldMargaret kozielDrug administrationInnoviva incSecurities exchangeJolla pharmaceutical companyEntasis therapeutics incCenters for diseaseGlaxo group limitedInnoviva specialty therapeutics incExchange commissionWorld health organizationSpecialty therapeuticsChief executive officerInnoviva specialty

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults

XACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumannii-calcoaceticus complex, which can include those resistant to.

United statesMargaret kozielTragiannidisa acinetobacterPavel raifeldInnoviva incSecurities exchangeNational review drug discoveryDrug administrationJolla pharmaceutical companyEntasis therapeutics incWorld health organizationExchange commissionInternational journal of infectious diseaseCenters for diseaseGlaxo group limitedYuk national prevalence